Novartis is collaborating with the Bill & Melinda Gates Foundation to develop an in vivo sickle cell disease gene therapy with the aim to make it widely accessible to patients living in all parts of the world, including in low- and middle-income countries. Besides potentially creating a new cure for sickle cell disease, the ambitious project could help pioneer new access models for gene therapies in global settings.

By Goran Mijuk and Michael Mildner

Published on 26/04/2024